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Predictive Factors of Mortality in Population of Patients with 
Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a 
Korean PNH Registry 
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive, systemic, life-threatening 
disease, characterized by chronic uncontrolled complement activation. A retrospective 
analysis of 301 Korean PNH patients who had not received eculizumab was performed to 
systematically identify the clinical symptoms and signs predictive of mortality. PNH 
patients with hemolysis (lactate dehydrogenase [LDH] ≥ 1.5 × the upper limit of normal 
[ULN]) have a 4.8-fold higher mortality rate compared with the age- and sex-matched 
general population (P < 0.001). In contrast, patients with LDH < 1.5 × ULN have a similar 
mortality rate as the general population (P = 0.824). Thromboembolism (TE) (odds ratio 
[OR] 7.11; 95% confidence interval [CI] (3.052-16.562), renal impairment (OR, 2.953; 
95% CI, 1.116-7.818) and PNH-cytopenia (OR, 2.547; 95% CI, 1.159-5.597) are 
independent risk factors for mortality, with mortality rates 14-fold (P < 0.001), 8-fold  
(P < 0.001), and 6.2-fold (P < 0.001) greater than that of the age- and sex-matched 
general population, respectively. The combination of hemolysis and 1 or more of the 
clinical symptoms such as abdominal pain, chest pain, or dyspnea, resulted in a much 
greater increased mortality rate when compared with patients with just the individual 
symptom alone or just hemolysis. Early identification of risk factors related to mortality is 
crucial for the management of PNH. This trial was registered at www.clinicaltrials.gov as 
NCT01224483.
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INTRODUCTION
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematopoietic stem 
cell disorder whose clinical manifestations include intravascular hemolysis, thrombo-
embolism (TE) and bone marrow failure (1). Despite best supportive care 5 years mor-
tality was 35% (1). The development of TE is the major cause of morbidity and mortali-
ty among patients with PNH (2). 
 Pathophysiology of thrombosis is multifactorial and includes platelet activation, tox-
icity of free hemoglobin, nitric oxide depletion, absence of other glycosylphosphati-
dylinositol-linked proteins such as urokinase-type plasminogen activator receptor and 
endothelial dysfunction (3). We have previously reported that elevated hemolysis is as-
sociated with a significantly increased risk for thrombosis and that this risk is further 
increased by the presence of PNH-related symptoms such as abdominal pain, chest 
pain, dyspnea, or hemoglobinuria (4). There are only a few reports of risk factors asso-
ciated with mortality in PNH patients in the study with Caucasian population (1,2). 
 Eculizumab improves survival and effects a sustained improvement in symptoms in 
PNH patients (5-8), and anti-complement therapy need to be clarified based on the 
risk factors of PNH. To better understanding the risk factors associated with mortality 
in PNH, a retrospective analysis was performed on data from 301 Korean PNH patients 
enrolled with pre-eculizumab era in a nationwide registry. The aim of this study was to 
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describe the burden of disease in PNH patients with pre-eculi-
zumab era and to systematically identify the risk factors associ-
ated with mortality in these PNH patients. In addition, this study 
is ever the first-time analysis of demonstrating standard mortal-
ity ratio (SMR) in PNH patients. 
MATERIALS AND METHODS
The Aplastic Anemia Working Party of The Korean Society of 
Hematology has established a web-based nationwide Korean 
National PNH Registry that covers 41 years of PNH disease data. 
There are 9 institutions participating in the Korean National 
PNH Registry, which covers 96% of the Korean PNH popula-
tion. A retrospective chart review was performed on 301 pa-
tients identified with the diagnosis of PNH. Although the pa-
tients were enrolled into the registry between 2009 and 2010, 
the chart review included medical history data prior to registry 
enrollment. Patient data included in this Korean Registry were 
captured using an electronic case report form that collected pa-
tient demographics and medical history and PNH-specific in-
formation, including erythrocyte and granulocyte clone size, 
symptoms and complications, laboratory values, treatment, 
and where applicable, cause of death. 
 PNH was confirmed using flow cytometry. In patients diag-
nosed before the establishment of flow cytometry, a positive 
Ham or sucrose-lysis test was used. The PNH granulocyte and 
erythrocyte clone sizes were based on available data from chart 
reviews and were not limited to minimum clone size or flow 
methodology. 
 Elevated hemolysis was defined as a lactate dehydrogenase 
(LDH) level ≥ 1.5 times the upper limit of normal (ULN) (6,9-
11). LDH at diagnosis of PNH was chosen as a consistent point 
of reference for most analyses. In patients with elevated LDH at 
diagnosis, the occurrence of TE within 6 months of diagnosis 
was analyzed to determine the temporal relationship between 
LDH level and TE. Multiple TE events were defined in patients 
having more than 1 TE event. PNH-cytopenia was defined as 
PNH in the setting of other specified bone marrow disorder (8). 
 Clinical PNH symptoms, including abdominal pain, chest 
pain, dyspnea, and hemoglobinuria, were based on physician 
reporting in medical charts and did not necessarily include the 
symptom onset date. However, dates of diagnosis, flow cyto-
metric assessments, bone marrow transplant (BMT), TE, and 
death were accurately recorded. TE was calculated 2 ways, ei-
ther as the occurrence at a specific time point or as the cumula-
tive incidence over a specific time period. The cumulative inci-
dence of TE was collected for the time periods prior to diagno-
sis and post-diagnosis of PNH. Transfusion requirements were 
categorized as 0 units, 1 to 4 units, or ≥ 5 units within the last 12 
months, where documented, prior to data collection. 
Statistical analysis
Binary variables were analyzed using univariate and multivari-
ate logistic regression. Potential risk factors included LDH ≥  
1.5 ×  ULN at the time of diagnosis, TE, impaired renal function 
(IRF), abdominal pain, chest pain, dyspnea, hemoglobinuria, 
granulocyte clone size and PNH-cytopenia. The percentage of 
glycosylphosphatidylinositol anchor protein-deficient granulo-
cytes was determined from flow cytometry assessments at di-
agnosis or conducted at the closest time point to diagnosis. LDH 
values at diagnosis were used in all analyses in an attempt to 
investigate their association with clinical outcomes. The null 
hypothesis of no association between mortality and a specific 
risk factor was tested using the log-likelihood ratio statistic, 
which follows a chi-square distribution. Results are presented 
as the odds ratio (OR) and the 95% confidence interval (CI). In 
the presence of a zero frequency, it is not strictly possible to es-
timate the ORs and the 95% CIs; thus, in a sensitivity analysis 
any zero values were imputed as 0.5. 
 Time-to-event variables, such as overall survival, were esti-
mated by the Kaplan-Meier method. The effects of prognostic 
factors on overall survival were analyzed using univariate or 
multivariate Cox proportional hazards models. Prognostic fac-
tors were similar to those stated above for the logistic regression 
analyses. The null hypothesis of equal hazards for death across 
the levels of the prognostic factor of interest was tested using 
the chi-square distribution. Relative risks are presented as haz-
ard ratios (HR) and 95% CIs. We analyzed each LDH cutoff val-
ues of 1.5 × , 3.0 × , and 5.0 ×  ULN by sensitivity, specificity and 
positive and negative likelihood ratios with 95% CIs. The Re-
ceiver Operating Characteristic Curve (ROC) plotted sensitivity 
(y-axis) against 1 minus the specificity (x-axis). 
 The Standard Mortality Ratio (SMR) is the ratio of the ob-
served mortality rate in the PNH population to the expected 
mortality rate of the age- and sex-matched subjects in the na-
tional population. The Korean National Mortality rates were 
provided for each year from 1983 to 2009 and for 5-year age 
groups: 5-9, 10-14, 75-79, and ≥ 80 years (www.kostat.go.kr). 
The expected number of deaths for males and females were 
calculated separately for purposes of comparison with the gen-
eral population and then summed to obtain the total number 
of expected deaths. The Statistics Korea (KOSTAT, www.kostat.
go.kr) provided cause of death for any patient in the study who 
was lost to follow up at the hospital where they were treated. 
Ethics statement
This study was conducted in accordance with the Declaration 
of Helsinki and was reviewed and approved by the institutional 
review board of the participating hospitals including Seoul St. 
Mary’s Hospital (No. KC10RSME0270). Informed consent was 
exempted by the board. 
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RESULTS 
Patient characteristics
Patients (n = 301) from the Korean PNH Registry were evaluat-
ed for signs, symptoms, and outcomes. A summary of patient 
demographics, medical history, and PNH-specific information 
for the 301 PNH patients is provided in Table 1. The median age 
at diagnosis was 37 years (range: 8-88 years), median follow-up 
time from diagnosis was 6.6 years (range: 0-28.8 years), and 
there was an approximately equal numbers of male and female 
patients. Based on physician-recorded medical charts, 42% of 
patients had a history of aplastic anemia (AA) and 6.3% had a 
history of myelodysplastic syndrome (MDS) either before or af-
ter diagnosis of PNH from the medical chart written by physi-
cians. Overall, 46.5% of patients (n = 140) were categorized as 
having PNH-cytopenia. Diagnosis of PNH by flow cytometry 
was reported for 236 patients (78.4%), Ham’s and sucrose tests 
for 56 patients (18.6%), Ham’s test only for seven patients (2.3%), 
and sucrose test only for two patients (< 1%). Further analysis 
showed that there were no significant differences in age, preva-
lence of TE, or early mortality between patients diagnosed us-
ing the different methods (data not shown). The median granu-
locyte and erythrocyte clone sizes were 48.8% and 28.1%, re-
spectively. At diagnosis, 76.3% of the patients with recorded LDH 
levels (171/224) had elevated hemolysis. The most frequently 
reported clinical symptoms were hemoglobinuria (56.1% of pa-
tients) and abdominal pain (46.8% of patients). Cases of hemo-
globinuria were probably self-reported macroscopic hemoglo-
binuria as it was not objectively assessed. TE was reported in 54 
(17.9%) patients and IRF was reported in 17% of patients. Fifty-
one patients (16.9%) reported IRF, defined as a history of acute 
renal failure (ARF) or estimated glomerular filtration rate (eGFR) 
of < 60 mL/min/1.73 m2 captured before or after diagnosis of 
PNH. Forty-four patients (14.6%) had a recorded history of ARF, 
and 26 (8.6%) had chronic eGFR < 60 mL/min/1.73 m2. One-
third of patients who reported IRF had both history of ARF at 
diagnosis and eGFR < 60 mL/min/1.73 m2. Corticosteroids 
were the most frequently used treatment in this patient popula-
tion. Of the 39 patients treated with opioids, 29 (74.4%) had ab-
dominal pain. Forty-one percent of patients had no documen-
tation of transfusion. Overall, 37 patients (12.3%) received BMT 
from related or unrelated donors. None of patients received ec-
ulizumab. 
Risk factors for mortality
During the median follow-up period (6.6 years; range 0-28.8), 
43 of the patients (14.3%) died. TE, IRF, and PNH-cytopenia 
were reported in 23 (53.5%), 7 (16.3%), and 27 (63%) of these 
patients, respectively, although these symptoms were not nec-
essarily reported as the cause of death. There were significantly 
more patient deaths reported in PNH patients with LDH ≥ 1.5 ×  
ULN at diagnosis (n = 28; 16.4 %) compared with patients with 
LDH < 1.5 × ULN (n = 2; 3.7%; P = 0.009). Of the patients with 
LDH ≥ 1.5 × ULN, 7 (4.1%) died within 1 year compared with 
none of the patients with LDH < 1.5 × ULN. 
 Twenty-three out of 54 patients (46.2%) with a history of TE 
died after a median time of 8 months (range: 1-17 years) as a 
direct result of a TE. Multiple TE events were reported in 10 of 
these patients (43.5%) with the remaining 13 patients experi-
encing a single TE event. The multivariate Cox proportional 
hazards model showed a statistically significant association for 
mortality with both multiple (HR, 6.3; 95% CI, 2.96-13.55; P <  
0.001) and one TE event also had a significantly increased risk 
of mortality (HR, 4.5; 95% CI, 2.3-9.1; P < 0.001) when compared 
with patients without TE. 
 Univariate analyses showed that significant predictors of 
mortality were TE (P < 0.001), IRF (P = 0.001), LDH ≥ 1.5 ×  
ULN (P = 0.009), PNH-cytopenia (P = 0.023), abdominal pain 
(P = 0.026), and dyspnea/chest pain (P = 0.026) (Table 2). Mul-
tivariate analyses indicated that only the first of these predictors 
(i.e. TE, IRF, and PNH-cytopenia) were significantly associated 
with an increased risk of mortality (P < 0.001, P = 0.029, and 
P = 0.020, respectively) (Table 2). Elevated levels of LDH and 
abdominal pain were not independent risk factors for mortality 
in the multivariate regression analysis (P = 0.159 and P = 0.162, 
respectively) although hemoglobinuria approached significance 
(P = 0.073). 
 A ROC analysis was performed as a sensitivity analysis com-
paring LDH concentrations at diagnosis of ≥ 1.5 vs. < 1.5 ×  ULN, 
≥ 3.0 vs. < 3.0 ×  ULN, and ≥ 5.0 vs. < 5.0 ×  ULN at diagnosis 
and compared the mortality of patients with LDH < 1.5, < 3.0 ×  
or < 5.0 ×  ULN. The results showed that the sensitivity, speci-
Table 1. Patient characteristics
Patient demographics n = 301
Age, yr
   Median (range)
   Mean (SD)
37 (8-88)
39.3 (15.4)
Patients < 40 yr, No. (%) 172 (57.1)
Gender, female, No. (%) 149 (49.5)
Additional bone marrow disorder, No. (%)
   Aplastic anemia
   Myelodysplastic syndrome
121 (40.2)
19 (6.3)
PNH granulocyte clone size, % (n = 195)
   Median (range)
   Mean (SD)
48.8 (0-100)
49.5 (30.8)
PNH RBC clone size, % (n = 199)
   Median
   Mean (SD)
28.1 (0-99.8)
33.2 (27.8)
LDH, fold above ULN (n = 224)
   Median (range)
   Mean (SD)
  ≥ 1.5 × ULN, No. (%)
4.10 (0.2-36.3)
5.6 (5.5)
171 (76.3)
Follow-up since diagnosis, yr
   Median (range)
   Mean (SD)
6.6 (0-28.8)
7.8 (6.0)
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ficity, and negative positive value (NPV) of elevated LDH at 
baseline as a predictor of mortality was 93.3% (28/30), 26.3%, 
and 96.2% (51/53), respectively, for LDH ≥ 1.5 ×  ULN; 70.0% 
(21/30), 43.3%, and 90.3% (84/93), respectively, for LDH ≥ 3.0 ×  
ULN; and 56.7% (17/30), 60.3%, and 90.0% (106/130), respec-
tively, for LDH ≥ 5.0 ×  ULN. The analysis showed that neither 
LDH > 3.0 ×  ULN nor LDH > 5.0 ×  ULN, were associated with 
a significant increase in mortality (P = 0.162 and P = 0.082, re-
spectively; Fig. 1A). The relationship between mortality and 
LDH cutoff value was also analyzed by logistic regression. The 
univariate OR was 4.99, 95% CI (1.15-21.70), P = 0.009 for pa-
tients with LDH cutoff value ≥ 1.5 ×  ULN, but was non-signifi-
cant with multivariate analysis (OR, 5.71; 95% CI, 0.67-47.22; 
P = 0.122). For LDH cutoff values of ≥ 3 × , and > 5 ×  ULN the 
association with mortality was not statistically significant. The 
univariate OR for both of these groups was 1.78 (P = 0.162) and 
1.99 (P = 0.082), respectively (Fig. 1B). 
Mortality according to supportive treatment
Overall, 13 of the 137 patients (9.5%) who remained transfusion 
free from the time of diagnosis prior to entry in the registry died 
compared with 8 of the 44 patients (18.2%) who had received 1 
to 4 units of packed red blood cells and 22 of the 120 patients 
(18.3%) who had received more than 5 units. The association 
between number of transfusions and mortality was not statisti-
cally significant (P = 0.088). The overall median duration of 
Table 2. Univariate and multivariate analysis of risk factors of mortality
Risk factors for mortality
Univariate analysis Multivariate analysis
P value Odds ratio (95% CI) P value Odds ratio (95% CI)
TE < 0.001 8.42 (4.15-17.08) < 0.001 7.110 (3.052-16.562)
IRF 0.001 3.41 (1.66-7.02) 0.029 2.953 (1.116-7.818)
PNH-cytopenia 0.023 2.17 ( 1.11-4.21) 0.020 2.547 (1.159- 5.597)
LDH ≥ 1.5 ×  ULN 0.009 4.99 (1.15-21.70) 0.159 3.204 (0.633-16.230)
Abdominal pain 0.026 2.10 (1.08-4.08) 0.162 1.828 (0.785-4.256)
Dyspnea/Chest pain 0.026 2.09 (1.086-4.024) 0.855 1.077 (0.487-2.381)
Hemoglobinuria 0.636 0.86 (0.45-1.63) 0.073 0.449 (0.187-1.077)
Clone size 0.391 1.01 (0.99-1.02) 0.744 0.995 (0.967-1.024)
CI, confidence interval; IRF, impaired renal function; LDH, lactate dehydrogenase; TE, thromboembolism; ULN, upper limit of normal. 
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Fig. 1. Impact of LDH in PNH patients. (A) Receiver operating characteristic curve of LDH cutoff for mortality, (B) Logistic regression analysis of the association of LDH ≥ 1.5, 
≥ 3.0 ×  and ≥ 5.0 ×  ULN at diagnosis and mortality. 
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Table 3. Standard mortality ratio according to risk factors
Patient population
SMR vs. age- and sex-matched 
general population
SMR (95% CI) P value
Total PNH patients (n = 301) 3.89 (2.73-5.05) < 0.001
No TE (n = 247) 2.13 (1.19-3.06) < 0.001
TE (n = 54) 13.92 (8.23-19.61) < 0.001
LDH < 1.5 ×  ULN (n = 53) 1.17 (0.00-2.79) 0.824
LDH ≥ 1.5 ×  ULN (n = 171) 4.81 (3.03-6.59) < 0.001
No IRF (n = 251) 3.06 (1.93-4.20) < 0.001
IRF (n = 50) 7.81 (3.86-11.77) < 0.001
Classic PNH  (n = 157) 4.4 (2.72-6.23) < 0.001
PNH-Cytopenia (n = 107) 6.2 (4.71-9.34) < 0.001
No abdominal pain (n = 159) 2.87 (1.46-4.28) < 0.001
Abdominal pain (n = 142) 4.92 (3.06-6.77) < 0.001
LDH ≥ 1.5 ×  ULN + abdominal pain (n = 92) 6.55 (3.60-9.49) < 0.001
No dyspnea (n = 189) 3.42 (1.95-4.88) < 0.001
Dyspnea (n = 112) 4.48 (2.61-6.35) < 0.001
LDH ≥ 1.5 ×  ULN + dyspnea (n = 58) 5.58 (2.85-8.32) < 0.001
No chest pain (n = 263) 3.82 (2.57-5.06) < 0.001
Chest pain (n = 38) 4.29 (1.11-7.47) < 0.001
LDH ≥ 1.5 ×  ULN + chest pain (n = 24) 5.72 (0.71-10.73) < 0.001
SMR, standard mortality ratio; CI, confidence interval; PNH, paroxysmal nocturnal he-
moglobinuria; LDH, lactate dehydrogenase; ULN, upper limit of normal; TE, thrombo-
embolism; IRF, impaired renal function.
Fig. 2. Kaplan-Meier survival of PNH patients compared with age- and gender-matched general population. (A) Patients with TE had a 14-fold higher mortality rate compared 
with the general population (standard mortality ratio [SMR] = 13.9; 95% confidence interval [CI], 8.2-19.6; P < 0.001). (B) Patients with cytopenia had a mortality rate 6.2-fold 
greater than the age- and gender-matched general population (SMR = 6.2; 95% CI, 4.7-9.3; P < 0.001). (C) Patients with impaired renal function (IRF) had a mortality rate 7.8-
fold greater than the age- and gender-matched general population (SMR = 7.8; 95% CI, 3.9-11.8; P < 0.001). (D) PNH patients with lactate dehydrogenase (LDH) ≥ 1.5 times 
the upper limit of normal (ULN) had a 5.0-fold greater risk for mortality compared with patients with LDH <1.5 × ULN (95% CI, 1.15-21.70; P = 0.009). PNH patients with LDH 
≥ 1.5 × ULN had a 4.8-fold higher mortality rate compared with the general population (SMR = 4.8; 95% CI, 3.0-6.6; P < 0.001). 
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corticosteroid use for patients included in this study was 5.42 
years. A Kaplan-Meier analysis showed that there was no differ-
ence in mortality between the 104 patients who either received 
corticosteroids for > 5.4 years (13%) compared with the 197 
patients who either received corticosteroids for < 5.4 years or 
had not received corticosteroids at all (15%; P = 0.520). Eleven 
out of the 44 patients (25.0%) with a history of anticoagulant 
use during the course of disease died, with 10 of these patients 
(90.9%) having a history of TE. The hazard ratio of death for pa-
tients with a history of anticoagulant compared with those with-
out a history of anticoagulant use was 2.34 times (95% CI, 1.078-
5.094, P = 0.036). 
Standard mortality ratio 
Table 3 presents the calculated SMR for this population of PNH 
patients compared with an age- and gender-matched general 
Korean population. Overall, a diagnosis of PNH increased the 
risk of mortality by 3.9-fold (P < 0.001). The greatest risk factor 
for mortality was a TE, which increased mortality by 13.9-fold 
compared with the general population (P < 0.001; Fig. 2A). Oth-
er significant risk factors, compared with an age- and gender 
matched population (P < 0.001 in each case) included, IRF (7.8-
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fold increase), PNH-cytopenia (6.2-fold increase), classic PNH, 
i.e. patients with overt hemolysis, elevated reticulocyte count, 
elevated LDH, and normocellular to hypercellular bone mar-
row (4.4-fold increase) and LDH ≥ 1.5 ×  ULN (4.8-fold increase) 
(Fig. 2B to D). Patients without evidence of elevated hemolysis 
(LDH < 1.5 × ULN) were the only subset of patients with a mor-
tality rate similar to that of the age- and gender-matched popu-
lation (SMR = 1.17; P = 0.824). Symptomatic risk factors for 
higher mortality rates compared with the general population 
included abdominal pain (4.92-fold increase; P < 0.001), dys-
pnea (4.48-fold increase; P < 0.001), and chest pain (4.29-fold 
increase; P < 0.001). Patients with both one of these symptoms 
and LDH ≥ 1.5 × ULN at diagnosis had SMR values that were 
approximately 25% (dyspnea) or 33% (abdominal pain and 
chest pain) higher than for the overall subset of patients with 
these individual symptoms alone (Table 3). 
Cause of death 
Cause of death was attributed to septicemia/infection in 14 of 
the 43 patients who died (32.6%), TE in 7 patients (16.3%), bleed-
ing in 4 patients (9.3%), clonal evolution (acute myeloid leuke-
mia [AML] and MDS) in 3 patients (7.0%), and renal failure in 1 
patient (2.3%). Mortality related to treatment with allogeneic 
BMT was 14% (n = 6). Ten of the 14 patients (71.4%) with a cause 
of death of septicemia/infection and 3 of the 4 patients (75%) 
who died from bleeding were diagnosed with PNH-cytopenia. 
The remaining 8 patients (18.6%) died from causes non-related 
to PNH (including other malignancy and unknown origins). 
DISCUSSION 
Our retrospective analysis of 301 patients enrolled in the Kore-
an National PNH Registry demonstrated the incidence of throm-
bosis in these patients was 17.9% (4). According to previous ret-
rospective PNH studies, the incidence of thrombosis ranges 
from 6.2% to 39% (1,12,13) with a retrospective French study of 
460 PNH patients demonstrating 10-year cumulative incidence 
of 31% (12). Recently it has been reported that the incidence of 
thrombosis in PNH is likely to be underestimated as a result of 
evidence of subclinical pulmonary embolism or myocardial 
ischemia observed in 6 of 10 patients in one study (3) and evi-
dence of subclinical myocardial damage in 2 of 10 patients in 
another study (14). These subclinical thromboses can lead to 
long-term organ damage as reflected by compromised cardiac 
function in the majority of these patients (14). Thrombosis has 
been reported as the leading cause of mortality in patients with 
PNH with 29% to 44% of patients suffering from at least one TE 
event during the course of their disease (1,2,6). In our retrospec-
tive study of 301 patients, the relative risk of mortality with TE 
was robust and confirmed across several relevant analyses. As-
sessment of the medical history of our study population not 
only identified patients with a TE event, but showed that there 
was progression of existing TE events across multiple sites, de-
spite the use of anticoagulants from which we have concluded 
that the administration of anticoagulation therapy to patients 
with PNH has little, if any effect on thrombosis management 
and patient survival. A prospective follow-up study from the In-
ternational PNH registry including over 1,600 patients world-
wide, may provide more definite information on the incidence 
and influence of thrombosis in PNH (15). 
 None of previous research showed a survival data in a large 
population with PNH compared to SMR. In this study, IRF is an 
independent risk factor for mortality among Korean patients 
with PNH. Patients with IRF have a mortality rate 8-fold higher 
than that of a general population (P < 0.001). One report found 
that between 8% and 18% of PNH deaths are caused by renal 
failure (13). It has been reported that hemolytic PNH patients 
manifested progressive renal dysfunction over time, which sug-
gests that IRF is a late-stage consequence of chronic hemolysis 
(5). 
 We report here PNH-cytopenia patients have a significantly 
greater risk of mortality compared with classic PNH patients. In 
contrast to classic PNH, which manifests with overt hemolysis, 
an elevated reticulocyte count, an elevated LDH, and a normo-
cellular to hypercellular bone marrow (16), patients with PNH-
cytopenia have a hypocellular bone marrow and seldom dem-
onstrate signs and symptoms of hemolysis as these patients 
have small populations of PNH cells; symptoms of anemia, 
thrombocytopenia and neutropenia are usually a consequence 
of bone marrow failure (17). Despite these different clinical 
presentations, the long-term outcomes have been reported to 
be similar in both groups of patients (2,18). In patients with 
PNH-cytopenia risk factors for negative long-term outcomes 
have been identified as an ANC < 0.5 × 109/L, infection, and 
evolution to MDS/AML (2,18). Therefore PNH-cytopenia might 
be a separate disease entity from classic PNH. Distinguishing 
between classical PNH and PNH-cytopenia is particularly im-
portant because if the PNH patients have severe cytopenia, im-
munosuppressive therapy or allogeneic BMT should be consid-
ered as a first-line therapy. 
 LDH was not found to be an independent risk factor for mor-
tality in this study. This finding is probably because of the inclu-
sion of TE, IRF, and history of AA or MDS in the multivariate 
model, which are strong predictors of mortality. LDH concen-
trations will fluctuate over time and as mortality can occur a 
significant time after PNH diagnosis, this may be why LDH was 
not an independent factor for mortality in our model. The ROC 
analysis showed that LDH ≥ 1.5 × ULN is a more sensitive and 
specific predictor than LDH ≥ 3.0 ×  and ≥ 5.0 × ULN which 
suggests LDH ≥ 1.5 × ULN is a realistic clinical measurement 
for identification of hemolysis. Further evidence of this was 
seen from the results of the logistic regression analysis which 
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also confirmed LDH ≥ 1.5 × ULN is a significant predictor of 
mortality. Taken together, these data confirm that uncontrolled 
complement activation leads to increase risk of mortality and 
demonstrates PNH patients with LDH ≥ 1.5 × ULN (a measure 
of complement activation) is a predictor for poor outcomes. 
 PNH patients with hemolysis have a mortality rate 4.8-fold 
higher than the age and gender-matched general population 
(P < 0.001). In contrast, there was no difference in mortality 
rates between PNH patients with LDH < 1.5 × ULN and a heal thy 
age- and gender-matched Korean population (P = 0.824). In-
terestingly, the combination of hemolysis and one or more of 
the clinical symptoms such as abdominal pain, chest pain or 
dyspnea, had a much greater mortality rate when compared to 
patients with individual symptoms or hemolysis alone. These 
symptoms may be a consequence of progressive organ damage 
such as gastrointestinal tract, heart, and lungs, due to chronic 
hemolysis and complement activity. In addition to contributing 
to mortality, symptoms such as abdominal pain, chest pain, 
and dyspnea contribute to the debilitating quality of life in PNH 
patients (19,20). Therefore once a diagnosis of PNH has been 
confirmed, clinical symptoms should be carefully monitored. 
Early therapeutic intervention administered in order to mini-
mize the adverse clinical effects of hemolysis and reduce mor-
tality in all PNH patients. 
 In the era of eculizumab, chronic hemolysis-related to mor-
tality in PNH can be controlled by an anti-complement inhibi-
tor. Survival of eculizumab-treated patients has significantly 
improved compared with those not treated with eculizumab 
and was similar to an age- and gender-matched general popu-
lation (7). This retrospective study reports the risk for mortality 
in a cohort of PNH patients who had not received eculizumab 
which suggests that in an era of this anti-complement inhibitor 
the natural course of PNH and survival of patients with this dis-
ease can be changed. 
 In summary, PNH patients with hemolysis (LDH ≥ 1.5 ×  ULN) 
have a 4.8-fold increase in mortality rate compared with the 
general population. The combination of hemolysis and one or 
more of the clinical symptoms such as abdominal pain, chest 
pain, and dyspnea, had much greater increased mortality rate. 
TE, IRF, and PNH-cytopenia are the independent predictors of 
mortality. Early identification of risk factors related to mortality 
is crucial for the management of PNH. 
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